Popular on eTradeWire
- Flush Gallery Presents Moral Injury, a group show, at Hercules Art Studio - 171
- BSM COO and Digital Strategist Daniel Burns Shares Effective Client Management at SE Ranking's Workshop - 120
- Florida Native Plant Society PBC Opposes Destruction of Lands at Jonathan Dickinson State Park - 120
- Concrete Engine Unveils First Product Demo at Rally Innovation 2024 - 119
- League of Women Voters PBC to Present Nonpartisan ELECTION EXPO 2024 on Sept 30 - 116
- Parsley Unveils New Integrations and Enhanced Features to Streamline Recruiting - 115
- Get Ready for Fun: A New Sports Center is Coming Soon To Colony Ridge! - 115
- Newly Appointed Holman Pastors Continue Lawson's Legacy - 111
- Big News for Colony Ridge Community: A New High School Is Coming Soon! - 110
- John Vuitton CEO of John Vuitton Entertainment, Earns MRAA Palladium Certification for "Tank Moves" - 103
Similar on eTradeWire
- Com-Guard.com, Inc. Announces its iTrakHealthAI™ with Artificial Intelligence. Apple Approved
- Comfort Dental South Western Ave Proud to Offer Oral Appliance Treatment for Sleep Apnea in Oklahoma
- Restore Your Smile with Comfort Dental Montrose's Dental Implant Services
- Comfort Dental Mile High Wants to Remind Patients of Its Comprehensive Dental Implants Services
- Local Spokane Research Company Wins NIH STTR Grant
- Emory Healthcare Systemwide Allied Health Hiring Event at the High Museum of Art
- Fast & Reliable Emergency Dental Care Now Available in Knoxville
- Nix nausea with Sea-Band® Nausea Relief Bands!
- HandicapMD Expands Leading Telemedicine Services for Disabled Parking Permits in Florida
- Over 700 Amazings Featured on "Meet The Amazings" Facebook Page
YouthBio Therapeutics Announces Significant Results from Joint Study with Dr. Ocampo Demonstrating Amelioration of Age-Related Cognitive Decline
eTradeWire News/10777794
SEATTLE - eTradeWire -- YouthBio Therapeutics (YouthBio), a pioneering longevity biotechnology company developing partial reprogramming-based gene therapies, today announced significant research results from its collaboration with Dr. Alejandro Ocampo, Professor at the University of Lausanne and a leading figure in aging research whose pioneering work has given rise to the partial reprogramming field.
The study, titled "Neuron-specific partial reprogramming in the dentate gyrus impacts mouse behavior and ameliorates age-related decline in memory and learning," demonstrates that brain-specific induction of partial reprogramming can ameliorate cognitive decline associated with aging. These findings add to the growing body of evidence for the therapeutic potential of in vivo partial reprogramming for the prevention and treatment of neurodegenerative disorders.
Key Findings
This study used two different approaches: a neuron-specific transgenic reprogrammable mouse model and a neuron-specific targeted lentiviral delivery of OSKM reprogramming factors. Both methods showed that partial reprogramming of adult neurons in the dentate gyrus of the hippocampus impacts animal behavior and cognitive function, and mitigates age-related decline in memory and learning.
"These exciting findings from our collaboration with Dr. Ocampo validate our approach and highlight the transformative potential of partial reprogramming in combating age-related cognitive decline," said Yuri Deigin, CEO and co-founder of YouthBio. "We are thrilled to see such promising results and are committed to advancing this research further."
Dr. Ocampo added, "I am delighted to collaborate with YouthBio to accelerate clinical translation of partial cellular reprogramming for treating age-related diseases, particularly neurodegenerative conditions. It is also very exciting to see other research groups demonstrating lifespan extension in wildtype mice through partial reprogramming. I believe that once we fully understand how to use this approach in a tissue-specific manner – something that YouthBio has recognized since the company's inception – we will see even greater increases in lifespan and more beneficial therapeutic effects in various disease models."
More on eTradeWire News
"The potential of partial reprogramming for brain rejuvenation and the treatment of neurodegenerative disorders is very promising," said João Pedro de Magalhães, Ph.D., Chief Scientific Officer of YouthBio. "Our recent findings suggest that partial reprogramming could play a significant role in addressing age-related cognitive decline. While there is still much to learn and refine, these early results are encouraging and provide a solid foundation for further research. We are cautiously optimistic that with continued investigation, we can develop effective therapies that may one day benefit patients suffering from conditions like Alzheimer's disease."
Future Plans and Alzheimer's Research
YouthBio is committed to investigating the use of partial reprogramming in the CNS with a particular focus on Alzheimer's disease. In another study using transgenic ARTE10 mice treated with brain-specific inducible OSKM vectors, YouthBio observed reduced amyloid beta levels and a lower brain plaque burden in pivotal areas such as the hippocampus, and improved cognitive performance in behavioral tests compared to untreated controls. Based on these promising results, YouthBio has filed a provisional patent application with the USPTO.
YouthBio's results are independently validated by a team of researchers from Altos Labs, the University of Barcelona, and the Max Planck Institute, who demonstrated favorable outcomes in preventing Alzheimer's symptoms through brain-specific partial reprogramming in a 5xFAD mouse model. Their study, "Expansion of the Neocortex and Protection from Neurodegeneration by In Vivo Transient Reprogramming," corroborates YouthBio's positive findings.
"Our positive Alzheimer's data, along with the independent positive results by Altos Labs and its collaborators, reinforces our confidence in partial reprogramming's ability to provide a novel treatment paradigm for neurodegenerative conditions," said Deigin. "Our next key milestone is to bring our Alzheimer's therapy to clinical trials, and we are fully committed to achieving this goal."
More on eTradeWire News
Clinical Trials and Beyond
YouthBio aims to advance its Alzheimer's disease therapy to clinical trials within three years. During this period, the company will conduct the necessary preclinical studies, GMP manufacturing, and regulatory preparations essential for filing an Investigational New Drug (IND) application with the FDA.
Concurrently, YouthBio will continue its discovery program, led by CSO Dr. João Pedro de Magalhães, to identify superior rejuvenating factors beyond the Yamanaka factors for use in subsequent generations of its tissue-specific gene therapies. The company will also conduct several proof-of-concept animal studies in other CNS indications and continue its progeria program.
In their progeria program, YouthBio was granted a Rare Pediatric Disease Designation by the FDA for YB-001 for the treatment of Hutchinson-Gilford progeria syndrome (HGPS). This designation makes YouthBio eligible to receive a Priority Review Voucher (PRV) if YB-001 is approved for treating progeria. The PRV can be redeemed for an expedited priority review of any subsequent marketing application or it can be sold. Historical PRV transaction values have exceeded $100mm, reaching as high as $350mm.
***
About YouthBio Therapeutics, Inc.
YouthBio Therapeutics (https://youthbiotx.com) is a longevity company developing gene therapies that leverage partial reprogramming to restore a more youthful gene expression profile in targeted cells, leading to positive therapeutic effects in corresponding organs. It is currently focused on brain-specific gene therapies targeting CNS diseases, with Alzheimer's disease being the primary program.
The study, titled "Neuron-specific partial reprogramming in the dentate gyrus impacts mouse behavior and ameliorates age-related decline in memory and learning," demonstrates that brain-specific induction of partial reprogramming can ameliorate cognitive decline associated with aging. These findings add to the growing body of evidence for the therapeutic potential of in vivo partial reprogramming for the prevention and treatment of neurodegenerative disorders.
Key Findings
This study used two different approaches: a neuron-specific transgenic reprogrammable mouse model and a neuron-specific targeted lentiviral delivery of OSKM reprogramming factors. Both methods showed that partial reprogramming of adult neurons in the dentate gyrus of the hippocampus impacts animal behavior and cognitive function, and mitigates age-related decline in memory and learning.
"These exciting findings from our collaboration with Dr. Ocampo validate our approach and highlight the transformative potential of partial reprogramming in combating age-related cognitive decline," said Yuri Deigin, CEO and co-founder of YouthBio. "We are thrilled to see such promising results and are committed to advancing this research further."
Dr. Ocampo added, "I am delighted to collaborate with YouthBio to accelerate clinical translation of partial cellular reprogramming for treating age-related diseases, particularly neurodegenerative conditions. It is also very exciting to see other research groups demonstrating lifespan extension in wildtype mice through partial reprogramming. I believe that once we fully understand how to use this approach in a tissue-specific manner – something that YouthBio has recognized since the company's inception – we will see even greater increases in lifespan and more beneficial therapeutic effects in various disease models."
More on eTradeWire News
- Author Releases Third Contemporary Christian Novel
- California State Society NSDAR Celebrates Fall Council And New Administration
- Pre-Order Your New Favorite Thanksgiving Children's Book Now!
- Best Books for Boys: The Christian Mystery Series That Reluctant Readers Can't Put Down!
- College-bound: Warrior Homes of Collier awards scholarships to local veterans, family members
"The potential of partial reprogramming for brain rejuvenation and the treatment of neurodegenerative disorders is very promising," said João Pedro de Magalhães, Ph.D., Chief Scientific Officer of YouthBio. "Our recent findings suggest that partial reprogramming could play a significant role in addressing age-related cognitive decline. While there is still much to learn and refine, these early results are encouraging and provide a solid foundation for further research. We are cautiously optimistic that with continued investigation, we can develop effective therapies that may one day benefit patients suffering from conditions like Alzheimer's disease."
Future Plans and Alzheimer's Research
YouthBio is committed to investigating the use of partial reprogramming in the CNS with a particular focus on Alzheimer's disease. In another study using transgenic ARTE10 mice treated with brain-specific inducible OSKM vectors, YouthBio observed reduced amyloid beta levels and a lower brain plaque burden in pivotal areas such as the hippocampus, and improved cognitive performance in behavioral tests compared to untreated controls. Based on these promising results, YouthBio has filed a provisional patent application with the USPTO.
YouthBio's results are independently validated by a team of researchers from Altos Labs, the University of Barcelona, and the Max Planck Institute, who demonstrated favorable outcomes in preventing Alzheimer's symptoms through brain-specific partial reprogramming in a 5xFAD mouse model. Their study, "Expansion of the Neocortex and Protection from Neurodegeneration by In Vivo Transient Reprogramming," corroborates YouthBio's positive findings.
"Our positive Alzheimer's data, along with the independent positive results by Altos Labs and its collaborators, reinforces our confidence in partial reprogramming's ability to provide a novel treatment paradigm for neurodegenerative conditions," said Deigin. "Our next key milestone is to bring our Alzheimer's therapy to clinical trials, and we are fully committed to achieving this goal."
More on eTradeWire News
- Com-Guard.com, Inc. Announces its iTrakHealthAI™ with Artificial Intelligence. Apple Approved
- Cozy Up with Adirondack Fragrance Farm's New Soy Wax Melts
- Cobb County Democratic Committee Presents "Horizon of Hope: HERstory in the Making"
- TBOX Christmas Bar Crawl Returns to Chicago for Year 28 this December
- Happy House Cleaning In Support Of Patients Recovering From Cancer
Clinical Trials and Beyond
YouthBio aims to advance its Alzheimer's disease therapy to clinical trials within three years. During this period, the company will conduct the necessary preclinical studies, GMP manufacturing, and regulatory preparations essential for filing an Investigational New Drug (IND) application with the FDA.
Concurrently, YouthBio will continue its discovery program, led by CSO Dr. João Pedro de Magalhães, to identify superior rejuvenating factors beyond the Yamanaka factors for use in subsequent generations of its tissue-specific gene therapies. The company will also conduct several proof-of-concept animal studies in other CNS indications and continue its progeria program.
In their progeria program, YouthBio was granted a Rare Pediatric Disease Designation by the FDA for YB-001 for the treatment of Hutchinson-Gilford progeria syndrome (HGPS). This designation makes YouthBio eligible to receive a Priority Review Voucher (PRV) if YB-001 is approved for treating progeria. The PRV can be redeemed for an expedited priority review of any subsequent marketing application or it can be sold. Historical PRV transaction values have exceeded $100mm, reaching as high as $350mm.
***
About YouthBio Therapeutics, Inc.
YouthBio Therapeutics (https://youthbiotx.com) is a longevity company developing gene therapies that leverage partial reprogramming to restore a more youthful gene expression profile in targeted cells, leading to positive therapeutic effects in corresponding organs. It is currently focused on brain-specific gene therapies targeting CNS diseases, with Alzheimer's disease being the primary program.
Source: YouthBio Therapeutics
0 Comments
Latest on eTradeWire News
- Looking for a perfect office space for our small business!?
- Evergreen Property Partners Announces DJ Van Keuren's Recognition as One of the World's Top 50 Family Capital Advisors
- NBA Champion Derek Anderson and Jamie Anderson Celebrate Anniversary and Community Impact
- Dallas Cowboys Sign the State of Nayarit as their Official Mexican Tourism Destination
- A conversation with renowned sociologist Boaventura de Sousa Santos on his five decade career
- Secret gardens – how to visit Europe's little-known but breathtaking monastic gardens
- Science from Scientists Expands National Footprint to Woburn
- David Boland, Inc. Awarded $9.7M Construction Contract With U.S. Army Corps of Engineers, Mobile
- Broadway's Rock of Ages Band® Brings Electrifying '80s Rock Hits to the Weinberg Center
- Local Spokane Research Company Wins NIH STTR Grant
- Emory Healthcare Systemwide Allied Health Hiring Event at the High Museum of Art
- Local Contractor Highlights Key Fall Home Improvement Projects That Add Value to OKC Homes
- SOAR Community Network Hosts Fireside Chat with Victor Hoskins of FCEDA on Workforce Development
- TurnMississippiBlue.org Pledges A New Way Forward
- Fast & Reliable Emergency Dental Care Now Available in Knoxville
- Breaking News: Southern Utah Adventure Center Unveils Epic Guided Tours for Unforgettable Adventures
- knus Secures Spot in Respected Hatch City Bridge Foundation Accelerator Program
- Breaking News: Southern Utah Adventure Center Joins Trail Hero for an Unmissable Off-Road Adventure!
- Nix nausea with Sea-Band® Nausea Relief Bands!
- Busiest August for travel job candidates since 2017